NCT05022342 2026-02-23
SPEAR
Novartis
Completed
Clinical Trials
8 trialsNCT07347600 2026-02-20
reaINAVO
Hoffmann-La Roche
Recruiting
NCT04967248 2025-12-04
A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting
Novartis
Terminated
NCT07096024 2025-08-28
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
Pfizer
Completed
NCT04916509 2023-06-06
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region
Pfizer
Completed
NCT02753686 2023-02-15
Treat ER+ight
Novartis
Completed
NCT05140655 2021-12-01
Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-
Dr. Reddy's Laboratories SAS
Unknown
NCT00660803 2010-01-21
Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer
AstraZeneca
Completed